LIST OF PUBLICATIONS

Nimulid Tablet Nimulid Transgel Nimulid Suspension Nimulid Injection
Nimulid+Cetirizine Nimulid+Piprine Nimulid Nugel Nimulid MD
Nimulid Safeinject Pangraf Panimun Panimun Bioral
Alphadol Enivac Enivac HB Giro (Ornidazole)
Manyana Tablets Manyana Injection Bukatel ZINC-Naproxen
0394 Rifampicin Lovastatin + Niacin-ER Atorvastatin and Niacin-ER
Atorvastatin and Ezetimibe Mirtazapine Pentavalent Vaccine Tacrolimus
Ciprofloxacin + Ornidazole Glizid M Glizid MR Betaglim
Others      

 

NIMULID TABLET 

  1. Sangeeta Sharma, S. Rastogi, V. Gupta, D. Rohtagi, and P. Gulati. 
    Comparative Efficacy and safety of Nimesulide versus Piroxicam in Osteoarthritis with Special Reference to Chondroprotection. 
    Am. J of Therapeutics 1999;6(4):191-197
     
  2. V. Roy, U. Gupta, S Sharma, B. K. Dhaon, N P. Singh, P. Gulati.
    Comparative efficacy and tolerability of nimesulide and Piroxicam in osteoartheritis with specific reference to chondroprotection: A double blind randomised study
    J Indian Med. Assoc. 1999;97(10):442 - 445
     
  3. V. K. Sharma, R. Srivastav, Sangeeta Sharma, D. Rohtagi.
    Comparative efficacy and safety of nimesulide vs Piroxicam in osteoartheritis.
    Indian J of Orthopaedics. July 1999; 33(3):212-216
     
  4. A Wanchu, SD Deodhar, A Sud, P Bambery.
    An 8 week double blind comparative study of efficacy and safety of nimesulide and Piroxicam in patient with Rheumatoid arthritis
    APLAR J of Rheumatology 1999;3(2):115-118
     
  5. Gupta R.L., Chaudhary A., Sethi H.C., et al
    Efficacy and tolerability of Nimesulide in post operative pain of anoretal and inguinoscrotal surgery.
    Hospital Today, July 1998; 3(7):407-409.
                                                                                                                      (details...)
     
  6. Dhaon B.K., Singh O.P. and Sharma S.
    Double-blind randomized comparative evaluation of efficacy and safety of Nimulid (Nimesulide) and Diclofenac in osteoarthritis.
    Indian Journal of Orthopaedics, Apr. 1998; 32(2):91-93.
                                                                                                                      (details...)
     
  7. Batabanova R.M.
    Nimulid - A new drug for treating osteoarthrosis.
    Clinical Pharmacology and Therapy, 1997; 6(2):8-10.
     
  8. Balabonova R.M.
    Nimulid-A new non-steroidal anti-inflammatory drug
    South Russian Medical Journal, 1997; 1:23-26.
     
  9. Ivan Zgradie
    Comparison of therapeutic efficacy of Nimesulide and Diclofenc in patients with degenerative Joint disease.
    Journal of the Indian Medical Association, April 1999; 97 (4): 119-123.
                                                                                                                      (details...)
     
  10. V. K. Sharma, R. Srivastav, Sangeeta Sharma and D. Rohtagi.
    Comparative efficacy and safety of Nimesutide vs Piroxicam in Osteoarthritis.
    Indian Journal of Orthopaedics, July 1999; 33 (3): 212-216.
     
  11. S Sharna, Rastogi S, Gupta V., D Rohtagi and P. Gulati.
    Comparative efficacy and safety of Nimesulide vs Piroxicam in osteoarthritis with special reference to chondroprotection.
    American Journal of Therapeutics, 1999; 6:191-197.
     
  12. Roy V., Gupta U., Sharma S., Dhaon B. K., Singh N.P., Gulati P.
    Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chrondroprotection: A double blind randomised study.
    Journal of the Indian Medical Association (JIMA), 1999; 97(10):442-445.
                                                                                                                      (details...)
     
  13. S K Kulkarni, Naveen K Jain.
    Is there a rationale for nimesulide and paracetamol combination?
    Indian Journal of Pharmacology, 1999; 31:444-445.
     
  14. Silva Dobric, Viktorija, Dragojevic-Simic., Bokonjic.
    Protective efficacy of nimesulide in paraquat-poisoned mice.
    Acta Veteriharia, 2000; 50(1): 31-36.

(TOP^)
  

NIMULID TRANSGEL

  1. Seema A Rajsingh, Raman Kanojia, Ashish Gulati, Manu Sehgal.
    Safety and efficacy of Nimulid Transgel in painful musculoskeletal conditions: A Post - marketing Study.
    The Anticeptic 2004; 101(10):432
     

  2. Dhaon BK, Singh OP, Gupta SP, Sharma DR et al.
    Efficacy and safety of nimesulide transdermal gel versus Diclofenac and Piroxicam gel in patients with acute musculoskeletal condition    .
    Indian Journal of Orthopaedic, 2000; 34(4):288 - 292.
     

  3. Gupta S.K., Prakash J., Awor L, et al.
    Anti inflammatory activity of topical nimesulide gel in various experimental modes.
    Inflammation Research, 1996; 45:590-592.
     

  4. Dhaon B.K., Farooque M.F., Sharma D.R. and Bhutani S.
    Open labelled clinical evaluation of local application of Nimesulide Trandermal gel in painful musculoskeletal conditions.
    Indian Journal of Orthopaedics, Apr. 1998;32(2):75 - 78.
                                                                                                                      (details...)
     

  5. SenguptaS.,VelpandianT., Kabir S.R. and Gupta S.K.
    Analgesic efficacy and pharmacokinetics of topical Nimesulide gel in healthy human volunteers: double-blind comparison with Piroxicam, Diclofanc and Placebo.
    European Journal of Clinical Pharmacology, 1998; 54:541-547.
      

  6. Sengupta S., Velpandian T., Sapra P., Mathur P. and Gupta S.K.
    Comparative Analgesic efficacy of Nimesulide and Diclofenac gel after topical application on the skin.
    Skin Pharmacol Appl Skin Physiol, 1998; 11:273-278.
     

  7. Dhaon BK, Singh OP, Gupta SP, Sharma DR and Bhutani S.
    Efficacy and safety of nimesulide transdermal gel versus Diclofenac and Piroxicam gel in patients with acute musculoskeletal condition.
    Indian Journal of Orthopaedics, 2000;34(4):288 - 292.
                                                                                                                      (details...)

(TOP^)

NIMULID SUSPENSION

  1. Comparison of antipyretic effect of Nimesulide and Paracetamol on children attending a secondary level hospital.
    Indian Pediatrics 2002 May; 39: 473 - 477.
     

  2. Efficacy of Nimesulide in pain relief after day care surgery.
    Indian Pediatrics 2002 Feb; 39: 178 – 182.
     

  3. Antipyretic effects of Nimesulide, Paracetamol and Ibuprofen – Paracetamol.
    Indian Journal of Pediatrics 2000; 67(12): 865 – 870.
     

  4. Double blind, placebo controlled study of the efficacy and tolerability of Nimesulide administered orally in acute bronchial asthma.
    American Journal of Therapeutics 2002; 9: 281 – 287.
     

  5. Goyal P.K., ChandraJ., Unnikrishnan G., Kumari Sand Passah S.M.
    Double-blind randomized comparative evaluation of Nimesulide and Paracetamol as antipyretics.
    Indian Pediatrics, Jun.1998, 35:519-522. (details...)

NIMULID INJECTION

  1. Gupta S.K., Velpandian T., Mathur P. and Sengupta S.
    Comparative analgesic activity of Nimesulide and Diclofenac by intramuscular route: Correlation with pharmacokinetic profile of Nimesulide.
    Pharmacology, 1998:56:137-143.
     

  2. N.J. Gogtay, R. Mhatre, S.S. Dalvi, S. Desai, A. Gupta and N.A. Kshirsagar (Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Bombay, India)
    A Randomised, Crossover, Assessor-Blind Study of the Pharmacokinetics of Parenteral Nimesulide versus Placebo in Healthy Indian Volunteers.
                                                                                                                  (details...)

NIMULID + CETIRIZINE

  1. Rewari S and Gupta U. Modification of Antihistamine Activity of Cetirizine by Nimesulide. Journal of Association of Physicians of India 1999; 47(4): 389-392.
     

  2. Rewari S. and Gupta U.
    Modification of Antihistamine Activity of Cetirizine by Nimesulide
    Journal of Association of Physicians of India (JAPI), 1999; VOL47(4): 389-392.
                                                                                                                      (details...)

NIMULID + PIPERINE

  1. Gupta S. K., Velpandian T, Sengupta S. etal.
    Influence of Piperine on Nimesulide induced antinociceptions.
    Phytotherapy Research, 1998, 12:266-269.

(TOP^)

 

NIMULID NUGEL
  1. Raj Bahadur, D R Sharma and Anjala Sikri.
    Comparative analgesic efficacy and safety of topical nimesulide multicomponent transdermal gel in patients with acute  musculoskeletal conditions: double blind comparison with Diclofenac gel.
    Scientific Oral presentation, 54 Indian Pharmaceutical Congress, 2002, Pune, 2002; E7, pg.         71.
NIMULID MD

  1. Dhaon BK, Balain B, Sharma DR and Singh P.
    Evaluation of efficacy and safety of Nimesulide Mouth Dissolving Tablets (Nimulid MD - 100mg) in patients of acute low back pain. 
    The Indian Practitioner 2001; 54(6: 417 - 422
     

  2. Karan RS, Garg SK, Bhargava VK, Sharma DR and Singh P.
    A randomised, two treatment single dose, crossover bioavailability study on Nimesulide Mouth Dissolving Tablets 100mg (Nimulid MD) comparing with conventional nimesulide formulation. 
    The Indian Practitioner 2001; 54(10):703 - 706
NIMULID SAFEINJECT
  1. Gogtay NJ, Mhatre R, Dalvi SS, Desai S, Gupta A and Kshirsagar N.  A randomised, crossover, assessor blind study of the pharmacokinetics of parenteral Nimesulide versus placebo in healthy Indian volunteers.  Clin Drug Invest 2002; 22(1):17 - 23
     
  2. Seema A Rajsingh.
    Drug profile of Nimulid SafeInject (Nimesulide Injection).
    The Anticeptic 2004; 101(10):431

PANGRAF
  1. The Safety And Efficacy Of Tacrolimus In Living Related Renal Transplant Recipients.
    Abstract presented in ISOT 2004.

PANIMUN

  1. Sachdeva A., Gulati R.. Gupta U., Bapna J.S.
    Comparative Bioavailability of two brands of cyclosporin
    Indian Journal of Pharmacology; 1997; 29:135 -137.

PANIMUN BIORAL

  1. Sud K, Singh B, Pandey R, Sakhuja V et al.
    Bioequivalence of two microemulsive preparations of Cyclosporine in renal transplant recipients with stable graft functions.
    Indian Journal of Nephrology, 1999; 87-91.
     

  2. RD Kulkarni, L Ramamurthy, Bankim Chauhan.
    Relative bioavailability of two oral dosage forms of Cyclosporine A.
    Indian Jr. of Nephrology, 1999;9(3):84-86.
     

  3. Kulkarni RD, Ramamurthy L, Chauhan B, Sharma DR et al.
    Bioequivalence of two marketed formulations of Cyclosporine A.
    Indian Journal of Pharmacology, 2000; 32(6): 394-395.
     

  4. Gulati R., Sharma S. and Gupta U.
    Pharmacokinetics of cyclosporin from conventional and new microemulsion formulation in healthy volunteers.
    Journal of the Association of Physicians of India (JAPI) 1998; Vol. 46(10), 860-863.
                                                                                                                      (details...)
     

  5. Singh S. and Sharma D. R.
    A review of absorption of characteristics of micoremulsion cyclosporine products over the last 2 years in Indian subjects
    Journal of the Indian Medical Association (JIMA), July 1999; 97(7):292-293.
                                                                                                                      (details...)
     

  6. H. Jauhari, S. Wadhawan, K. A. Yashpal, S. Sharma, R. Wadhawan & S. Singh Monitoring of cyclosporine trough levels at various post-transplant periods in renal graft recipients on microemulsion cyclosporine (Panimun Bioral)
    Oral Presentation in 6th Annual Conference of Indian Society of Nephrology Northern Chapter (G. S. V. M. Medical College, Kanpur).
                                                                                                                      (details...)
     

  7. Kulkarni R. D, Chauhan B. and Ramamurthy L.
    Relative bioavalability of two oral dosage forms of cyclosporine A
    Indian Journal of Nephrology, 1999; 9(3):84-86
                                                                                                                      (details...)
     

  8. Sud K, Singh B, Pandey R, Kohli HS, Jha V, Gupta KL and Sakhuja V.
    Bioequivalence of two microemulsive preparations of cyclosporine in renal transplant recipients with stable graft functions.
    Indian Journal of Nephrology, 1999;87-91.
                                                                                                                      (details...)
     

  9. Wadhawan S., Jauhari H. and Singh S.
    Cyclosporine A Trough Levels in diabetic and non-diabetic renal transplant patients.
    Presentation in 6th congress of the Asian Society of Transplantation, Singapore, 1999,224.
                                                                                                                      (details...)
     

  10. H Jouhari, S Wadhawan, Yashpal and Ashok Kumar.
    Cyclosporine trough levels in Indian Renal Graft recipient
    Journal of the Indian Medical Association (JIMA), 1999; 97(11):476-477.
                                                                                                                      (details...)
     

  11. Subhash Verma, Neelam Verma, Pankaj Malhotra, Sanjay Singh, and Deepika R. Sharma. 
    Cyclosporin A monotherapy in Young Indian Aplatic Anaemia patients.
    Journal of the Indian Medical Association (JIMA). 1999; 97(12):505-506.
                                                                                                                      (details...)
     

  12. Sud K, Sakhuja V, Pandey R, Singh B, Kohli HS, Jha V and Gupta KL.
    Bioequivalence of two microemulsive preparations of cyclosporine in renal transplant recipients with stable graft function.
    Poster Presentation in XXXth Annual Conference of Indian Society of Nephrology, November 26-28 (Patna), 1999, 23.
                                                                                                                      (details...)
     

  13. S Wadhawan, H. Jauhari, Ashok Kumar, D. Bhalla.
    Cyclosporine (CyA) Through Levels and CyA dosing in Indian Renal Allograft recipients.
    Poster Presentation in XXXth Annual Conference of Indian Society of Nephrology, November 26-28 (Patna), 1999, 24.
                                                                                                                      (details...)
     

  14. S Wadhawan, H. Jauhari, A Gupta and D. Bhalla.
    Cyclosporine dosing at various post renal transplant periods in 127 Indian patients.
    Poster Presentation in International CME in Nephrology, (International Certificate Course in Clinical Nephrology, September 28th - 30th (varanasi), 1999, 53.
                                                                                                                      (details...)
     

  15. S Wadhawan, H. Jauhari, A Gupta and D. Bhalla.
    Cost of Cyclosporine in post renal transplant period.
    Poster Presentation in XII Annual Conference of Indian Society of Organ Transplantation, ISOT2000, February 18th - 20th (PGIMER, Chandigarh), 2000, 32.
                                                                                                                      (details...)
     

  16. S Wadhawan, H. Jauhari, A Gupta and D. Bhalla.
    Cyclosporine dosing in renal transplants.
    Poster Presentation in III International Congress on Transplantation & Kidney Disease, January 6th - 9th (IKDRC, Ahmedabad), 2000, 72.
                                                                                                                      (details...)
     

  17. Wadhawan S, Jauhari H, Kumar A and Bhalla D.
    Cyclosporine dose in diabetic renal transplant patients.
    Poster Presentation in South -Asian Nephrology Congress At New Millennium & International CME - 2000, (AIIMS, New Delhi).
     

  18. Wadhawan S, Jauhari H and Singh S.
    Cyclosporine Trough levels in Diabetic and Nondiabetic Renal transplant patients.
    Transplantation Proceedings, November 2000; 1682 -1983.
     

  19. Kulkarni RD, Ramamurthy L, Chauhan B, Singh A, Singh S and Sharma DR.
    Bioequivalence of two marketed formulations of cyclopsorine A.
    Indian Journal of Pharmacology, 2000;32(6): 394-395 .

(TOP^)
  

ALPHADOL
  1. Osteoporosis epidemiology review and Panacea osteoporosis evaluation study.
    Journal of the Indian Medical Association 2000; 98(10): 657 – 659.

ENIVAC

  1. Kar P, JandwaniP., Khurana V., et al.
    Seroconversion with rDNA hepatitis B vaccine of Cuban origin.
    Indian Journal of Gastroenterology, 1997; 16(4): 161.
     

  2. Sethi G. R., Sharma S., Sudha S. and Rishi R. K.
    Immunogenicity of Recombinant Hepatitis B Vaccine in thalassemic Children.
    Indian Pediatrics, May 1999; 36: 498-501.
                                                                                                                      (details...)

  3. Sanjay Singh and Dr. Deepika R. Sharma.
    Tolerability of a recombinant DNA Hepatitis B Vaccine - Result of Post-Marketing Surveillance.
    Journal of Communicable Diseases, March 1999; 31(1): 53-55.
                                                                                                                      (details...)

  4. Kunal Das, R. K. Gupta, B. K. Sharma, V. Kumar, S. Singh & Kar P.,
    Evaluation of immunogenicity and reactogenicity of rDNA Hepatitis B Vaccine in subjects over the age of forty years.
    Oral Presentation in Indian Association for study of the liver. Pg. 24.
                                                                                                                      (details...)

  5. Kunal Das, P. Kar, Sanjay Singh, V. Kumar & B. K. Sharma.
    HLA phenotype and response to a single booster dose in non-responders to hepatiits B vaccination among age group more than forty years in North Indians.
    Poster presentation in 11th asian-pacific congress of gastroentrology. 8th Asian pacific congress of digestive endoscopy, March 10-14, 2000, Hong Kong, China, Pg.B32. Abstract No.A87.
     

  6. Jain A., Jandwani P., Gupta R. K., Kumar V. Mathur U.S. and Kar P.
    A Multicentric evaluation recombinant DNA Hepatitis B vaccine of Cuban origin.
    Tropical gastroenerology, 2000 (Jan- Mar); 21(1): 14 -17
     

  7. Kaur Harjeet, Mani A.
    Seroprotection following Enivac-HB, a recombinant hepatitis B Vaccine (Letter)
    Indian Journal of Gastroenterology; 2000; 19(1): 41.

(TOP^)
  

ENIVAC HB
 

  1. Zahid Hussain, Syed S Ali, Syed A Husain, Mohammad Raish, Deepika R Sharma, Premashis Kar
    Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India
    World J Gastroenterol 2005; 11(45): 7165-7168
                                                                                             (details...)
     

  2. Kunal Das, R.K. Gupta, V. Kumar, Sanjay Singh, P.Kar
    Association of HLA Phenotype with Primary Non-response to Recombinant Hepatitis B Vaccine: A Study from North India
    Tropical Gastroenterology, 204; 25:113-115
                                                                                         (details...)
     

  3. Arora NK, Ganguly S, Sharma D et al.
    Hepatitis B immunization in low birthweight infants: do they need an additional dose?
    Acta Pediatr 2002; 91: 995 – 1001.
     
  4. Kunal Das, R. K. Gupta, B. K. Sharma, V. Kumar, S. Singh & Kar P.
    Evaluation of immunogenicity and reactogenicity of rDNA Hepatitis B Vaccine in subjects over the age of forty years.
    Oral Presentation in Indian Association for study of the liver. Pg. 24.
     
  5. Zahid Hussain, S. Sohail Ali et al.
    Evaluation of immunogenicity and reactogenicity of Enivac HB (recombinant DNA Hepatitis B Vaccine) produced in India.
    Indian Journal of Gastroenterology. March 2004, Vol. 23(Suppl. 1).
     
  6. Kunal Das, R. K. Gupta, V. Kumar, P. Kar. 
    Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.  
    World JGastroenterol 2003; 9(5):1132-1134.
     
  7. Kunal Das, P. Kar, Sanjay Singh, V. Kumar & B. K. Sharma.
    HLA phenotype and response to a single booster dose in non-responders to hepatitis B vaccination among age group more than forty years in North Indians    .
    Poster presentation in 11th asian-pacific congress of gastroentrology. 8th Asian pacific congress of digestive endoscopy, March 10-14, 2000, Hong Kong, China, Pg.B32. Abstract No.A87.
     
  8. Swatee Bapat, Datta Joshi, S.S.Malik et al.
    Hepatitis B immunization in Adolescent Girls    .
    Indian Pediatrics, Oct 2001, Vol. 38: 1160-1162.
     
  9. Sethi GR, Sharma S, Sudha S and Rishi RK.
    Immunogenicity of Recombinant Hepatitis B Vaccine in thalassemic Children. Indian Pediatrics 1999; 36: 498-501.51. Sethi GR, Sharma S, Sudha S and Rishi RK. Immunogenicity of Recombinant Hepatitis B Vaccine in thalassemic Children.
    Indian Pediatrics 1999; 36: 498-501.
     
  10. Singh S and Sharma DR.
    Tolerability of a recombinant DNA Hepatitis B Vaccine - Result of Post-Marketing Surveillance.
    Journal of Communicable Diseases, 1999; 31(1): 53-55.
     
  11. Jain A, Jandwani P, Kar P et al.
    A Multicentric evaluation of recombinant DNA Hepatitis B vaccine of Cuban origin.
    Tropical Gastroenterology 2000; 21(1): 14 -17
     
  12. Kaur Harjeet, Mani A.
    Seroprotection following Enivac-HB, a recombinant hepatitis B Vaccine (Letter).
    Indian Journal of Gastroenterology; 2000; 19(1): 41.

GIRO (ORNIDAZOLE)

  1. Ramamurthy L, Kulkarni RD, Chauhan BL, Sharma DR et al. Relative bioavailability of two brands of Ornidazole in twelve healthy volunteers. JAPI, 2002 September; 50: 1149 – 1152

MANYANA TABLETS

  1. Chaudhary A. and Gupta R. L.
    Double-blind comparative prospective clinical evaluation of a combination antispasmodic-Manayana® (Diclofenac, Pitofenone and Fenpiverinium) and Baralgan (Analgin, Pitofenone and Fenpiverinium) in intestinal, biliary and ureteric colic.
    Journal of the Indian Medical Association 1999; 97(6): 244-245.
     

  2. Kulkarni S. K., Ninan I. and Singh A.
    Antispasmodic activity of diclofenac and its combination with pitofenone and fenpiverinium on rat colon.
    Indian Journal of Pharmacology, 1998; 30: 323-325.
     

  3. Chaudhary A. and Gupta R. L.
    Double-blind comparative prospective clinical evaluation of a combination antispasmodic-Manayana® (Diclofenac, Pitofenone and Fenpiverinium) and Baralgan (Analgin, Pitofenone and Fenpiverinium) in intestinal, biliary and ureteric colic.
    Journal of the Indian Medical Association (JIMA), June 1999; 97(6):244-245.

MANYANA INJECTION

  1. Golhar KB and Gupta RL.
    Open labeled evaluation of Manyana (A combination of Diclofenac + Pitofenone + Fenpiverinium) injection in Ureteric, Biliary and Intestinal spasm-A preliminary report.
    Journal of the Indian Medical Association 1999; 97(9):398-400.
     

  2. Kulkarni SK, Jain NK and Singh A.
    Antispasmodic activity of Diclofenac and its combination with pitofenone against acetylcho-line and barium chloride induced spasm of the guinea pig ileum.
    Indian Journal of Pharmacology, 1999; 31: 442-443.
     

  3. Golhar K.B. and Gupta R. L.
    Open labelled evaluation of Manyana (A combination of Diclofenac + Pitofenone + Fenpiverinium) injection in Ureteric, Biliary and Intestinal spasm-A preliminary report.
    Journal of the Indian Medical Association (JIMA) Sept. 1999; 97(9):398-400.
                                                                                                                                                     (details...)

  4. S K Kutkarni, N K Jain and Amarjit Singh.
    Antispasmodic activity of dictofeanac and its combination with pitofenone against acetylcho-line and barium chloride induced spasm of the guinea pig ileum.
    Indian Journal of Pharmacology, 1999; 31: 442-443.

Bukatel

  1. Evaluation of prochlorperazine buccal tablets (Bukatel) and metoclopramide oral tablets in the treatment of acute emesis.
    Journal of the Indian Medical Association 1999, 97(8): 346 - 347
     

  2. Clinical studies on efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine.
    Indian Journal of Pharmacology, 2000 Feb., 32(1): 65. (Abstract)
     

  3. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache 2002; 42(9): 896 – 902
     

  4. Dr. Adarsh Chaudhary, Sanjay Singh and Deepika R. Sharma.
    Evaluation of prochlorperazine buccal tablets (Bukatel) and metoclopramide oral tablets in the treatment of acute emesis.
    Journal of the Indian Medical Association (JIMA), August 1999, 97(8): 346 - 347
                                                                                                                                              (details...)

  5. Gulati RK. Sharma S, Prasad A and Nehru R.
    Clinical studies on efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine.
    Indian Journal of Pharmacology, 2000 Feb., 32(1): 65.

(TOP^)

ZINC-NAPROXEN

  1. Jain NK, Singh A & Kulkarni SK.
    Analgesic, anti-inflammatory and uicerogenic activity of a zinc-naproxen complex in mice and rats.
    Pharm and Pharmacol Commu, 1999; 5:599-602.

0394

  1. Sharma VK.
    Tuberculostatic activity of henna (Lawsonia inermis Linn.).
    Tubercle 1990; 71: 293 - 295.

(TOP^)

RIFAMPICIN

  1. Gupta U,
    Bioequivalence study of Rifampidn - A short communication
    JAPI

LOVASTATIN + NIACIN-ER

  1. Manoj Sharma, DR Sharma, RB Panwar, HS Hira, B. Mohan, SK Sharma and Rajeev Gupta.  Evaluation of efficacy and safety of Fixed dose of Lovastatin - Niacin ER combination in hyperlipidemic patients.  Indian Heart Journal 2004; 56:556 (Abstract)

ATORVASTATIN + NIACIN-ER

  1. Manoj Sharma, VT Shah, Raja Babu Panwar, MK Daga, Manuj Sharma, Vikram Singh and Deepika Sharma. Multicentric trial for evaluation of efficacy, safety and tolerability of fixed dose combination of Atorvastatin and Niacin-Extended Release in hyperlipidemic Indian patients. Indian Heart Journa,l 2004;56:557 (Abstract)

ATORVASTATIN + EZETIMIBE

  1. VT Shah, Rajeev Gupta, Raja Babu Panwar, MK Daga, Bishav Mohan, Naveen, Krutika Haria, Vikram Singh,  and Arani Chatterjee. Manoj Sharma et al.  Evaluation of efficacy, safety and tolerability of fixed dose combination of Atorvastatin and Ezetimibe in hyperlipidimic Indian patients. Indian Heart Journal, 2004; 56:558 (Abstract)

MIRTAZAPINE

  1. Gaurav Kumar, Raman Kanojia, Suhail Ali and Deepika R Sharma.  An open label, randomized trial to assess the efficacy and tolerability of Mirtazapine vs Amitriptyline in unipolar depression.  Poster Presentation at 56th Indian Pharmaceutical Congress, 2004, Kolkata.

PENTAVALENT VACCINE

  1. Syed Suhail Ali, Meenu Singh, Sudharao Chandrashekhar and R K Bansal. Open labelled, prospective, multicentric trial to evaluate the immunogenicity and reactogenicity of Pentavalent vaccine (Diptheria/ Tetanus Toxoid / w–Pertussis-r-DNA Hepatitis B and Haemophilus Influenzae Type b vaccine).  Poster Presentation in 12th Asean Pediatric Federation Conference, Nov. 26 - 28, 2004.  Pattaya, Thailand.  POSTER NO.: FP-F-22

TACROLIMUS

  1. V Sakhuja, M Minz, S Karthik Kumar, A Sharma, D Chakraborty, DR Sharma, HS Kohli, K Sud, KL Gupta, V Jha.  The safety and efficacy of Tacrolimus in living related renal transplant recipients.  XV Annual Conference of Indian Society of Organ Transplantation.  ISOT - 2004. 30th September - 2nd October 2004, Mumbai.

CIPROFLOXACIN + ORNIDAZOLE

  1. GN Saxena, A Govil, AK Bhatt, DR Sharma and Suhail Ali. Evaluation of efficacy and safety fixed dose combination of Ciprofloxacin and Ornidazole in patients suffering from diarrhea of mixed infection.  Scientific Oral presentation, 54th Indian Pharmaceutical Congress, Pune, 2002; E7, pg 67.

GLIZID M
  1. Bajpai N, Gulati Aand Chatterjee A

    A 4-6 Months Open Labelled, Multicentric, Non-comparative Study For Evaluation Of Efficacy, Safety And Tolerability Of Glizid-M In Type 2 Diabetes

     Glizid-M is the fixed dose combination of Gliclazide (80mg) and Metformin (500mg) indicated for the treatment of non-insulin dependent diabetes mellitus; type 2 diabetes with or without obesity in adults. The present post marketing surveillan ce evaluated the efficacy, safety and tolerability of Glizid-M in 497 patients with type 2 diabetes. It was an open labelled, non-comparative, multi centric study; which involved 26 investigators across the country. The total duration of protocol therapy was 4 weeks, whereas duration of study was 4-6 months. Assessment of the blood glucose levels was performed at the baseline, at 2nd week and at the end of the therapy (4th week). Safety parameters were assessed at week 2 and at the end of the therapy.
                                                                                                                                              (details...)


     
  2. Bajpai N, Singh A P , Chatterjee A

    An Open Labelled, Prospective, Non-comparative, Multicentric Post Marketing Experience for Evaluation of Efficacy and Safety of Glizid-M In Type 2 Diabetes.

    Glizid-M is the fixed dose combination of Gliclazide (80mg) and Metformin (500mg). The efficacy and safety of this combination therapy in type 2 diabetes has been evaluated in an open-label, prospective, non-comparative multicentric, phase IV study conducted in India over a period of 6 weeks in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. The superiority of the combination therapy and its effects on glycaemic parameters and lipid profile has been observed. A discussion of the same with brief review of literature has been presented here. (The Ind. Pract. 2005; 58(6): )
                                                                                                                                              (View Details...  )


 

GLIZID MR

  1. BAJPAI NIDHI., GULATI ASHISH., SHARMA DEEPIKA R.

    Evaluation of Glycemic Control, Safety and Tolerability of Glizid – MR in Type-2 Diabetes mellitus: A post Marketing Experience, During Short Term Therapy

    Glizid-MR, is the modified release (MR), formulation of the drug gliclazide and is given once daily. As with the common formulation of gliclazide, the modified release formulation is indicated in the treatment of type 2 diabetes, in adult subjects, when diet, exexecise and weight loss are insufficient to restore and adequate metabolic control.The present post marketing study, evaluated the glycemic control, safety and tolerability of Glizid- MR in 498 patients with type-2 diabetes in short term treatment. This study involved 21 doctors across the country. As per the doctors recording the overall response to the drugs was excellent to good and the drug was reportedly well tolerated. However, comparative studies with the drugs may further be beneficial to prove the above fact.

BETAGLIM
  1. Nidhi Bajpai, Ajit Pal Singh, Arani Chatterjee

    A Nine Months Open Labelled, Multicentric, Non-comparative Study for Evaluation of Efficacy (Glycaemic Control), Safety and Tolerability of BetaglimTM in Type- 2 Diabetes

    The present post marketing surveillance evaluated the efficacy, safety and tolerability of BetaglimTM (Glimepiride) in 558 patients with type 2 diabetes. It was an open labeled, non-comparative, multi centric study; which involved 35 investigators across the country. As per the doctors recording, the overall response to BetaglimTM was excellent to very good and the drug was reportedly well tolerated.

                                                                                                                   (details...)
 

 Other Pharmaceutical & Pharmacological Publications

  1. Kulkarni S.K., Jain N.K., Singh A. Cycloxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitor. Methods and Findings in Experimental and Clinical Pharmacology 200, 22 (5): 291 - 298.
     

  2. Singla A.K., Chawla M., Singh A. Nimesulide : Some pharmaceutical and Pharmacological Aspects - An Update. J. Pharm. Pharmacol. 2000, 52: 467 - 486.
     

  3. Aggarwal R., Mittal R., Singh A. Studies of Ion - Exchange Resin Complex of Chloroquine Phosphate. Drug Development and Industrial Pharmacy. 2000, 26(7). 773 - 776.
     

  4. Singla A.K., Chawla M., Singh A. Potential Applications of Carbomer in Oral Mucoadhesive Controlled Drug Delivery system : A Review. Drug Development and Industrial Pharmacy 2000, 26 (9) : 913 - 924.
     

  5. Mitra S., Datta A., Singh S.K., Singh A. 5-Hydroxytryptamine - inhibiting property of feverfew : role of parthenolide content. Acta Pharmacol Sin. 2000, (12), 1106 - 1114.
     

  6. Jain N.K., Patil C.S., Singh A., Kulkarni S.K. A simple technique to evaluate inflammatory pain alongwith anti-inflammatory activity in carrageen an-induced paw edema in rats : Ind. J. Pharmacol, 2001(33), 114 - 115.
     

  7. Kumar M., Singhal S.K., Singh A. Development and validation of a stability indicating HPLC assay method for cyclosporin in cyclosporine oral soluction USP. J Pharm Biomed Anal 2001 (25) 9 - 14.
     

  8. Jain N.K., Kulkarni S.K., Singh A. Differential antinociceptive effect of cyclooxygenase inhibitors in acetic acid induced chemonociception in mice. Analgesia 2001 (In press).
     

  9. Jain N.K., Kulkarni S.K., Singh A. Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions. European J Pharmacol 2001 (In press).
     

  10. Singh A., Singh P., Kapoor V.K. Nimesulide. Analytical Profiles of Drug Substances and Excipients ; Vol. 28; 2001 (In press)
     

  11. Vyas S.P., Singh A., Sihokar V. Ligands-receptor mediated drug delivery : an emerging paradigm in cellular drug targeting; Critical review in Therapeutic Drug Systems, 2001. (In Press).
     

  12. Kulkarni S.K., Jain N.K., Singh A. Nitric Oxide releasing-NSAIDs : A new dimension in Non Steroidal Anti-inflammatory Drugs. Drugs of Future 2001 (In Press)
     

  13. Kulkarni S.K., Jain N.K., Singh A. Cyclooxygenase isoenzymes : Their selective inhibitors. Pharmacology & Therapeutics in New Millenium, 2001 (In Press)
     

  14. Singh A., Mittra S., Singh S.K., Datta A. Feverfew In Herbal Medicines : Mechanism of action, edited by Kwan C.Y. Marcel Dekker, 2001 (In press)
     

  15. Jain N., Patil C.S., Kulkarni S.K., Singh A. Sildenafil - induced peripheral analgesia and activation of the nitric oxide - cyclic GMP pathway Brain Research 2001 (In press)
     

  16. Jain N., Kulkarni S.K., Singh A. Safety profile of nonsteroidal anti-inflammatory drugs in experimental animals. Communicated (2001) in Inflammopharmacology.


(TOP^)